DCLK1 and renal cell carcinoma: Ge et al. (2018) in their experiment have shown that DCLK1 long isoforms express CSC markers and are prognostic factors in RCC. DCLK1 and aldehyde dehydrogenase (ALDH) are connected on a biological level; thereby, increasing the possibility of forming a population of renal tumor stem cells that have high clonogenicity and resistance to chemo and radiotherapies (Ge et al., 2018). Studies targeting DCLK1 by specific monoclonal antibodies (mAb) have shown to inhibit tumorigenesis (Sureban et al., 2019; Cao et al., 2020).